PD-1 Inhibitor Clinical Trials

26 clinical trials for PD-1 Inhibitor across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer — RECRUITING · PHASE1
• LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study — RECRUITING · PHASE1
• Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer — RECRUITING · PHASE2
• Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC — RECRUITING · PHASE2
• Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer — RECRUITING · PHASE2
• Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC — RECRUITING · PHASE2
• HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma — RECRUITING
• Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell — RECRUITING · PHASE2
• Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody — RECRUITING
• Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma — RECRUITING · PHASE2
• Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis — ACTIVE_NOT_RECRUITING · PHASE1
• Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial — NOT_YET_RECRUITING · PHASE3
• Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. — ACTIVE_NOT_RECRUITING · PHASE1
• Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 — NOT_YET_RECRUITING · PHASE2
• Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer — ACTIVE_NOT_RECRUITING · NA
• Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer — NOT_YET_RECRUITING · PHASE2
• PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. — NOT_YET_RECRUITING · PHASE1
• Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders. — NOT_YET_RECRUITING · PHASE1
• Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer — NOT_YET_RECRUITING · PHASE1
• Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma — OTHER · PHASE2
• Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma — OTHER · PHASE2
• Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma — OTHER · PHASE2
• Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer — OTHER · PHASE2
• PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure — OTHER · PHASE2
• G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma — OTHER · PHASE1

Refine this search